Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 1
1964 2
1965 5
1969 1
1970 1
1972 2
1978 1
1979 1
1980 1
1981 1
1982 1
1984 1
1987 2
1989 1
1990 2
1991 1
1992 3
1993 3
1994 2
1995 5
1996 1
1998 4
1999 2
2000 1
2002 2
2003 2
2004 1
2005 2
2007 2
2008 1
2009 2
2010 8
2011 7
2012 5
2013 4
2014 3
2015 3
2016 7
2017 6
2018 7
2019 2
2020 4
2021 8
2022 3
2023 3
2024 14
2025 10
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA. Blair HA. Drugs. 2024 Apr;84(4):449-457. doi: 10.1007/s40265-024-02018-3. Epub 2024 Apr 9. Drugs. 2024. PMID: 38592603 Free PMC article. Review.
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree( ) (USA); Ryeqo( ) (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the management of moderate to sev …
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree( ) (USA) …
Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents.
Othman ER, Al-Hendy A, Mostafa R, Lambalk CB, Mijatovic V. Othman ER, et al. Int J Womens Health. 2024 Feb 27;16:309-321. doi: 10.2147/IJWH.S442357. eCollection 2024. Int J Womens Health. 2024. PMID: 38435758 Free PMC article. Review.
Current medical treatment options for endometriosis associated pains are inadequate. Evidence on effects of nonsteroidal anti-inflammatory drugs is scarce. ...Relugolix at an oral dose of 40 mg/day results in improvement in different forms of endometriosis related p …
Current medical treatment options for endometriosis associated pains are inadequate. Evidence on effects of nonsteroidal anti-inflamm …
Norethindrone acetate versus dienogest for pain relief in endometriosis related pain: A randomized controlled trial.
Gurbuz TB, Aslan K, Kasapoglu I, Muzii L, Uncu G. Gurbuz TB, et al. Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113940. doi: 10.1016/j.ejogrb.2025.113940. Epub 2025 Mar 29. Eur J Obstet Gynecol Reprod Biol. 2025. PMID: 40233572 Clinical Trial.
OBJECTIVE: To determine which progestin, norethindrone acetate (NETA) or dienogest, is more effective in alleviating pain associated with endometriosis? ...These findings suggest NETA 5 mg/day may be a better approach instead of dienogest for the endometri …
OBJECTIVE: To determine which progestin, norethindrone acetate (NETA) or dienogest, is more effective in alleviating pain asso …
Medical Management of Ovarian Endometriomas: A Systematic Review and Meta-analysis.
Eberle A, Nguyen DB, Smith JP, Mansour FW, Krishnamurthy S, Zakhari A. Eberle A, et al. Obstet Gynecol. 2024 Jan 1;143(1):53-66. doi: 10.1097/AOG.0000000000005444. Epub 2023 Nov 9. Obstet Gynecol. 2024. PMID: 37944155
Norethindrone acetate with aromatase inhibitor was also effective in reducing endometrioma volume (mean difference of log-transformed volume 1.47, 95% CI, 0.16-2.78, two studies, n=34 cysts). CONCLUSION: Medical management with dienogest, OCPs, GnRH agonists, nor …
Norethindrone acetate with aromatase inhibitor was also effective in reducing endometrioma volume (mean difference of log-tran …
Hormonal contraception in women with endometriosis: a systematic review.
Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Grandi G, et al. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61-70. doi: 10.1080/13625187.2018.1550576. Epub 2019 Jan 21. Eur J Contracept Reprod Health Care. 2019. PMID: 30664383
Main outcome measures were endometriosis-related pain (dysmenorrhoea, pelvic pain and dyspareunia), quality of life (QoL) and postoperative rate of disease recurrence during treatment. ...Only two COC preparations (ethinylestradiol [EE]/norethisterone acetate [NETA] …
Main outcome measures were endometriosis-related pain (dysmenorrhoea, pelvic pain and dyspareunia), quality of life (QoL) and postope …
Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.
Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, Somigliana E. Vercellini P, et al. Fertil Steril. 2016 Mar;105(3):734-743.e3. doi: 10.1016/j.fertnstert.2015.11.016. Epub 2015 Dec 8. Fertil Steril. 2016. PMID: 26677792 Free article.
OBJECTIVE: To assess the proportion of patients satisfied with their treatment before and after a systematic change from norethindrone acetate to dienogest as the first-line progestin for symptomatic endometriosis. ...PATIENT(S): The last 90 new consecutive …
OBJECTIVE: To assess the proportion of patients satisfied with their treatment before and after a systematic change from norethindrone …
Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills.
Casper RF. Casper RF. Fertil Steril. 2017 Mar;107(3):533-536. doi: 10.1016/j.fertnstert.2017.01.003. Epub 2017 Feb 2. Fertil Steril. 2017. PMID: 28162779 Free article. Review.
Biologic data and limited clinical evidence support a potential adverse effect of long-term use of OCPs on the progression of endometriosis. In contrast, there is randomized, controlled trial data to support the use of oral progestin-only treatment for pelvic pain associat …
Biologic data and limited clinical evidence support a potential adverse effect of long-term use of OCPs on the progression of endometrios …
The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis.
Thiel PS, Donders F, Kobylianskii A, Maheux-Lacroix S, Matelski J, Walsh C, Murji A. Thiel PS, et al. J Minim Invasive Gynecol. 2024 Apr;31(4):273-279. doi: 10.1016/j.jmig.2024.01.002. Epub 2024 Jan 6. J Minim Invasive Gynecol. 2024. PMID: 38190884
METHODS OF STUDY SELECTION: We included studies of premenopausal women undergoing hormonal treatment of endometriosis for 3 months. The authors excluded studies involving surgical intervention in the follow-up period and those using hormones to prevent endometrioma recurr …
METHODS OF STUDY SELECTION: We included studies of premenopausal women undergoing hormonal treatment of endometriosis for 3 months. …
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, Paszkowski M, Petraglia F, Renner SP, Patel A, Boolell M, Bestel E, Dolmans MM. Donnez J, et al. Hum Reprod. 2024 Jun 3;39(6):1208-1221. doi: 10.1093/humrep/deae076. Hum Reprod. 2024. PMID: 38648863 Free PMC article. Clinical Trial.
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demon …
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add …
The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K, Surrey E, Stanczyk FZ. Chwalisz K, et al. Reprod Sci. 2012 Jun;19(6):563-71. doi: 10.1177/1933719112438061. Epub 2012 Mar 27. Reprod Sci. 2012. PMID: 22457429 Review.
Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Noret …
Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormon …
137 results